CD274 and cancer: Given these correlations in other cancers, its immune relevance, and the growing place of ICIs in advanced NSCLC treatment, we assessed the ICR signature as a potential predictive biomarker for ICI response in a cohort of 162 patients with advanced NSCLC treated with anti-PD1/PDL1 ICI.